AtriCure, Inc. (ATRC)
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
- Symbol
- ATRC
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Market cap
- $3.05B
- 52 week range
- 25.36 - 61.47
Valuation
- Share price
- $59.96 (close of 2026-09-23)
- P/E (TTM)
- 282.52x
- Price to book
- 5.91x
- Price to free cash flow
- 57.42x
- Enterprise value
- $2.95B
- Book value per share
- $10.15
Price performance
| Period | Change |
|---|
| 1 day | +2.81% |
| 5 days | +6.65% |
| 1 month | +22.42% |
| 3 months | +110.83% |
| 6 months | +101.34% |
| Year to date | +51.57% |
| 1 year | +63.65% |
| 3 years | +45.82% |
| 5 years | -19.35% |
| 10 years | +271.50% |
| All time | +325.85% |
Profitability and growth
- Return on equity
- -2.33%
- Return on invested capital
- -2.37%
- Return on assets
- -1.75%
- Return on capital employed
- -1.65%
- Gross margin
- 74.98%
- Net margin
- -2.14%
- EBITDA margin
- 0.49%
- Revenue growth
- 14.88%
- Net income growth
- 74.39%
- Free cash flow growth
- 6381.07%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 1.74%
- Current ratio
- 4.22x
- Net debt to EBITDA
- -2.51x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $534.53M
- Cost of revenue
- $133.75M
- Gross profit
- $400.78M
- EBITDA
- $2.64M
- Net income
- $-11.45M
- Earnings per share
- $-0.24
- Research and development
- $99.21M
- Shares outstanding
- 47.75M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $534.53M | $400.78M | $-11.45M | $-0.24 |
| 2024-12-31 | $465.31M | $347.52M | $-44.70M | $-0.95 |
| 2023-12-31 | $399.25M | $300.37M | $-30.44M | $-0.66 |
| 2022-12-31 | $330.38M | $245.94M | $-46.47M | $-1.02 |
| 2021-12-31 | $274.33M | $205.86M | $50.20M | $1.11 |
| 2020-12-31 | $206.53M | $149.31M | $-48.16M | $-1.14 |
| 2019-12-31 | $230.81M | $170.34M | $-35.19M | $-0.94 |
| 2018-12-31 | $201.63M | $147.12M | $-21.14M | $-0.62 |
| 2017-12-31 | $174.72M | $126.16M | $-26.89M | $-0.83 |
| 2016-12-31 | $155.11M | $111.10M | $-33.34M | $-1.05 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 74.98% | -2.14% | -2.33% | -2.37% |
| 2024-12-31 | 74.69% | -9.61% | -9.70% | -9.71% |
| 2023-12-31 | 75.23% | -7.62% | -6.53% | -6.61% |
| 2022-12-31 | 74.44% | -14.06% | -10.17% | -10.40% |
| 2021-12-31 | 75.04% | 18.30% | 10.38% | 12.49% |
| 2020-12-31 | 72.29% | -23.32% | -11.68% | -18.26% |
| 2019-12-31 | 73.80% | -15.25% | -14.23% | -13.69% |
| 2018-12-31 | 72.97% | -10.48% | -8.48% | -9.92% |
| 2017-12-31 | 72.21% | -15.39% | -16.69% | -16.56% |
| 2016-12-31 | 71.63% | -21.49% | -19.79% | -20.99% |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $167.43M | $61.87M |
| 2024-12-31 | $122.72M | $61.87M |
| 2023-12-31 | $137.28M | $60.59M |
| 2022-12-31 | $121.11M | $56.83M |
| 2021-12-31 | $119.09M | $59.74M |
| 2020-12-31 | $244.22M | $53.44M |
| 2019-12-31 | $81.80M | $59.63M |
| 2018-12-31 | $124.40M | $35.57M |
| 2017-12-31 | $34.45M | $24.10M |
| 2016-12-31 | $44.01M | $23.89M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $48.28M | $44.69M |
| 2024-12-31 | $745.00K | $40.41M |
| 2023-12-31 | $-7.51M | $35.73M |
| 2022-12-31 | $-39.02M | $28.77M |
| 2021-12-31 | $-23.53M | $28.08M |
| 2020-12-31 | $-25.13M | $22.64M |
| 2019-12-31 | $-27.99M | $17.98M |
| 2018-12-31 | $-10.38M | $16.50M |
| 2017-12-31 | $-15.33M | $14.62M |
| 2016-12-31 | $-22.81M | $11.70M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $0.01
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-23 | Jun/2026 | $0.03 |
| 2026-05-05 | - | - |
| 2026-02-17 | - | - |
| 2025-10-29 | - | - |
| 2025-07-29 | - | - |
| 2025-04-29 | - | - |
| 2025-02-13 | - | - |
| 2025-02-12 | - | - |
Filings and sources
- Company website
- atricure.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · West Pharmaceutical Services Inc (WST) · Baxter International Inc (BAX) · Align Technology Inc (ALGN) · Cooper Companies, Inc. (COO) · Vertex Pharmaceuticals Inc (VRTX)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades